CYP3A4 and CBD Exposure (PubMed, 2026)

Tier 1: Established: peer-reviewed research or government health authority
Publisher: European Journal of Drug Metabolism and Pharmacokinetics (Jaisupa, Birgersson, Ashton, 2026; PMID 42728549) · Published: September 16, 2026 · Accessed: September 16, 2026

Visit the source ↗

Claims this source supports

• Ketoconazole, a CYP3A4 inhibitor, markedly reduced the in vitro intrinsic clearance of both CBD and its active metabolite 7-OH-CBD.
• CYP2C19 and CYP2C9 inhibitors produced only minor reductions in CBD clearance, pointing to CYP3A4 as the dominant route in this model.
• The authors frame this as a pharmacokinetic drug-drug interaction concern for CBD exposure, not as evidence of clinical harm.